ABSTRACT
To study the possibility of application of nootropics and antioxidants in the complex antiepileptic therapy, we examined 75 patients with symptomatic focal posttraumatic epilepsy. A statistically significant reduction in the number of epileptic seizures, improvement of cognitive function and quality of life of the patients as well as a decrease in the severity of depression and epileptic changes in the EEG were identified. The potentiation of antiepileptic activity of basic drugs, normalization of brain's electrical activity and reduction in EEG epileptiform activity, in particular coherent indicators of slow-wave activity, were noted after treatment with the antioxidant mexidol. A trend towards the improvement of neuropsychological performance and quality of life was observed. There was a lack of seizure aggravation typical of many nootropic drugs. Thus, phenotropil and mexidol can be recommended for complex treatment of symptomatic posttraumatic epilepsy.
Subject(s)
Antioxidants/therapeutic use , Epilepsy, Post-Traumatic/drug therapy , Nootropic Agents/therapeutic use , Adolescent , Adult , Cognition/drug effects , Cognition/physiology , Drug Therapy, Combination , Electroencephalography/drug effects , Epilepsy, Post-Traumatic/diagnosis , Epilepsy, Post-Traumatic/physiopathology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Picolines/therapeutic use , Piracetam/analogs & derivatives , Piracetam/therapeutic use , Treatment Outcome , Young AdultSubject(s)
Anticonvulsants/therapeutic use , Drug Resistance , Epilepsy/drug therapy , Humans , PrognosisABSTRACT
To search for association between the 163G>A polymorphism of the fatty acid binding protein 2 (FABP2) gene and intracellular transport of the valproic acid in the small intestines, 168 patients with different forms of epilepsy, aged from 1 to 89 years, and different illness duration have been studied. The patients received valproates (127 patients) and topiramate (41 patients) as a monotherapy. It has been shown that the 163G>A (Ala54Thr) polymorphism exerts an influence on effective dose of the valproic acid but not of topiramate.